We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.
- Authors
Ribaudo, Heather J; Haas, David W; Tierney, Camlin; Kim, Richard B; Wilkinson, Grant R; Gulick, Roy M; Clifford, David B; Marzolini, Catia; Fletcher, Courtney V; Tashima, Karen T; Kuritzkes, Daniel R; Acosta, Edward P; Adult AIDS Clinical Trials Group Study
- Abstract
Efavirenz has a long plasma half-life and a low genetic barrier to resistance. Simultaneously stopping treatment with all agents in efavirenz-containing regimens may result in functional efavirenz monotherapy that selects for drug-resistant human immunodeficiency virus type 1. Lower plasma efavirenz clearance is associated with a cytochrome P450 2B6 gene (CYP2B6) polymorphism (516G-->T) that is more frequent among African American individuals than among European American individuals.
- Publication
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Vol 42, Issue 3, p401
- ISSN
1537-6591
- Publication type
Journal Article
- DOI
10.1086/499364